por John R. Fischer
, Senior Reporter | July 09, 2021
Samsung Electronics’ mobile digital X-ray system, GM85 is now equipped with AI developed by South Korean manufacturer, VUNO Inc.
A diagnostic chest X-ray solution, VUNO Med-Chest X-ray is expected to help GM85 users instantly retrieve and deliver AI results upon scanning an image while the patient is still in the hospital.
"Incorporating VUNO's AI technology, we can introduce a more sophisticated mobile X-ray system with AI enabled CAD," said Woo-young Jang, Samsung Electronics' head of its DR business team.
Carestream Health is a leading provider of quality X-ray systems and detectors that are designed to maximize diagnostic confidence, workflow and patient satisfaction. Follow the link above to see our complete portfolio of digital radiography solutions.
VUNO Med-Chest X-ray is designed to accurately and immediately flag suspected chest abnormalities that indicate major pulmonary diseases such as tuberculosis and pneumonia. It also can identify lung cancer based on five of the most common thoracic findings: nodule/mass, pneumothorax, interstitial opacity, pleural effusion and consolidation. Its AI algorithm has been validated in academic journals and clinical settings for its improved clinical utility and efficiency, as well as its lightweight enabled integration capabilities.
GM85’s lightweight and ultra-compact design combines a broad range of advanced technology including a quick charging and long-lasting battery for enhanced user-convenience and superior image quality. With VUNO’s AI application, the solution is expected to be especially helpful in emergency rooms and intensive care units where real-time analysis is critical, as well as in medical environments with limited or no network connections.
“This collaboration will bring us closer to making our market-ready AI applications more accessible across the globe,” said Hyun-jun Kim, co-founder, and CEO of VUNO, in a statement.
VUNO-Med Chest X-ray is fully deployed in Korea and Europe. It is expected to be commercialized as part of GM85 in Korea and other major markets worldwide later this year.